HEADER IMMUNE SYSTEM 12-MAR-09 3GM0 TITLE ANTI-METHAMPHETAMINE SINGLE CHAIN FV IN COMPLEX WITH MDMA COMPND MOL_ID: 1; COMPND 2 MOLECULE: ANTI-METHAMPHETAMINE SINGLE CHAIN FV; COMPND 3 CHAIN: A; COMPND 4 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: MUS MUSCULUS; SOURCE 3 ORGANISM_COMMON: MOUSE; SOURCE 4 ORGANISM_TAXID: 10090; SOURCE 5 GENE: IGG; SOURCE 6 EXPRESSION_SYSTEM: PICHIA PASTORIS; SOURCE 7 EXPRESSION_SYSTEM_TAXID: 4922; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: KM71H; SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PPICZ-ALPHA KEYWDS ANTI-METHAMPHETAMINE ANTIBODY, SINGLE CHAIN FV, THERAPEUTIC ANTIBODY, KEYWDS 2 IMMUNE SYSTEM EXPDTA X-RAY DIFFRACTION AUTHOR R.CELIKEL,E.C.PETERSON,M.OWENS,K.I.VARUGHESE REVDAT 3 09-OCT-24 3GM0 1 REMARK HETSYN REVDAT 2 03-NOV-09 3GM0 1 JRNL REVDAT 1 06-OCT-09 3GM0 0 JRNL AUTH R.CELIKEL,E.C.PETERSON,S.M.OWENS,K.I.VARUGHESE JRNL TITL CRYSTAL STRUCTURES OF A THERAPEUTIC SINGLE CHAIN ANTIBODY IN JRNL TITL 2 COMPLEX WITH TWO DRUGS OF ABUSE-METHAMPHETAMINE AND JRNL TITL 3 3,4-METHYLENEDIOXYMETHAMPHETAMINE. JRNL REF PROTEIN SCI. V. 18 2336 2009 JRNL REFN ISSN 0961-8368 JRNL PMID 19760665 JRNL DOI 10.1002/PRO.244 REMARK 2 REMARK 2 RESOLUTION. 2.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : NULL REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 15.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 99.8 REMARK 3 NUMBER OF REFLECTIONS : 8316 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING SET) : 0.214 REMARK 3 FREE R VALUE : 0.271 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 7.100 REMARK 3 FREE R VALUE TEST SET COUNT : 592 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.40 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.67 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.3110 REMARK 3 BIN FREE R VALUE : 0.3450 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 163 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1797 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 14 REMARK 3 SOLVENT ATOMS : 77 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 39.04 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : 16.17000 REMARK 3 B22 (A**2) : -11.19400 REMARK 3 B33 (A**2) : -4.97600 REMARK 3 B12 (A**2) : 0.00000 REMARK 3 B13 (A**2) : 1.38200 REMARK 3 B23 (A**2) : 0.00000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.32 REMARK 3 ESD FROM SIGMAA (A) : 0.32 REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00 REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.007 REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : 66.94 REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : CNS_TOPPAR:PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : CNS_TOPPAR:WATER.PARAM REMARK 3 PARAMETER FILE 3 : MDMA.PARAM REMARK 3 PARAMETER FILE 4 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 TOPOLOGY FILE 2 : NULL REMARK 3 TOPOLOGY FILE 3 : NULL REMARK 3 TOPOLOGY FILE 4 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 3GM0 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 24-SEP-09. REMARK 100 THE DEPOSITION ID IS D_1000052027. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 18-JUN-08 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 8.3 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : SSRL REMARK 200 BEAMLINE : BL9-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.97945 REMARK 200 MONOCHROMATOR : SINGLE CRYSTAL BENT REMARK 200 MONOCHROMATOR REMARK 200 OPTICS : SINGLE CRYSTAL BENT REMARK 200 MONOCHROMATOR REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 315 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 8316 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.400 REMARK 200 RESOLUTION RANGE LOW (A) : 32.400 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : NULL REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 3.750 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.04500 REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.58 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.5 REMARK 200 DATA REDUNDANCY IN SHELL : 3.70 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.21000 REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: CNS REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 36.35 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 1.93 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 1.15M SODIUM CITRATE, 0.28M IMIDAZOLE REMARK 280 MALATE, PH 8.3, VAPOR DIFFUSION, TEMPERATURE 287K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 32.40300 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ASP A 1 REMARK 465 TYR A 2 REMARK 465 LYS A 3 REMARK 465 ASP A 4 REMARK 465 ASP A 5 REMARK 465 ASP A 6 REMARK 465 ASP A 7 REMARK 465 LYS A 8 REMARK 465 SER A 130 REMARK 465 GLY A 131 REMARK 465 GLY A 132 REMARK 465 GLY A 133 REMARK 465 GLY A 134 REMARK 465 PRO A 251 REMARK 465 HIS A 252 REMARK 465 HIS A 253 REMARK 465 HIS A 254 REMARK 465 HIS A 255 REMARK 465 HIS A 256 REMARK 465 HIS A 257 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PRO A 22 155.66 -44.08 REMARK 500 SER A 23 -23.75 67.52 REMARK 500 SER A 39 -171.00 -177.68 REMARK 500 LYS A 72 -63.54 -9.23 REMARK 500 ASP A 80 84.33 -151.31 REMARK 500 SER A 95 -9.10 -56.70 REMARK 500 ALA A 99 165.23 176.34 REMARK 500 SER A 125 106.22 -41.74 REMARK 500 THR A 192 -46.00 59.65 REMARK 500 ALA A 225 -169.95 175.56 REMARK 500 ARG A 249 103.66 97.30 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE B41 A 600 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 3GKZ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF A THERAPEUTIC SINGLE CHAIN ANTIBODY IN REMARK 900 COMPLEX METHAMPHETAMINE REMARK 999 REMARK 999 SEQUENCE REMARK 999 THE PROTEIN WAS CRYSTALLIZED AS A FUSION PROTEIN WHERE TWO CHAINS, REMARK 999 CHAIN H AND CHAIN L, WERE FUSED TOGETHER INTO ONE CHAIN USING A 15- REMARK 999 RESIDUE LINKER. THE SEQUENCE OF THE LINKER IS: GGGGS GGGGS GGGGS. REMARK 999 IN ADDITION, THERE IS A FLAG EPITOPE AT THE N-TERMINAL AND THERE IS REMARK 999 A HIS-TAG AT THE C-TERMINAL. PLEASE NOTE THAT THE AMINO ACID REMARK 999 NUMBERING IN THIS PDB FILE A SEQUENTIAL NUMBERING OF THE SCFV6H4 REMARK 999 SINGLE CHAIN ANTIBODY AMINO ACIDS DUE TO PDB POLICY. PLEASE SEE THE REMARK 999 ORIGINAL MANUSCRIPT FOR THE MORE COMMON KABAT AMINO ACID NUMBERING REMARK 999 SCHEME OF THE HEAVY AND LIGHT CHAIN RESIDUES. PLEASE USE THE REMARK 999 CORRELATION PROVIDED BELOW FOR CONVERTING TO KABAT NUMBERING SCHEME REMARK 999 USED IN OUR MANUSCRIPT. PDB NUMBER (PUBLICATION NUMBER): A9 (H1), REMARK 999 A90 (H82), A91 (H82A), A92 (H82B), A93 (H82C), A94 (H93), A110 (H99) REMARK 999 , A111 (H100A), A112 (H100B), A113 (H100C), A114 (H101), A141 (L1), REMARK 999 A167 (L27), A168 (L27A), A169 (L28), A247 (L106), A248 (L106A), REMARK 999 A249 (L107), HOH 505 (OW(5)), HOH 506 (OW(6)) DBREF 3GM0 A 1 257 PDB 3GM0 3GM0 1 257 SEQRES 1 A 257 ASP TYR LYS ASP ASP ASP ASP LYS GLU VAL GLN LEU GLN SEQRES 2 A 257 GLU SER GLY PRO SER LEU VAL LYS PRO SER GLN THR LEU SEQRES 3 A 257 SER LEU THR CYS SER VAL THR GLY ASP SER VAL THR SER SEQRES 4 A 257 GLY TYR TRP SER TRP ILE ARG GLN PHE PRO GLY ASN LYS SEQRES 5 A 257 LEU ASP TYR MET GLY TYR ILE SER TYR ARG GLY SER THR SEQRES 6 A 257 TYR TYR ASN PRO SER LEU LYS SER ARG ILE SER ILE THR SEQRES 7 A 257 ARG ASP THR SER LYS ASN GLN VAL TYR LEU GLN LEU LYS SEQRES 8 A 257 SER VAL SER SER GLU ASP THR ALA THR TYR TYR CYS SER SEQRES 9 A 257 TYR PHE ASP SER ASP ASP TYR ALA MET GLU TYR TRP GLY SEQRES 10 A 257 GLN GLY THR SER VAL THR VAL SER GLY GLY GLY GLY SER SEQRES 11 A 257 GLY GLY GLY GLY SER GLY GLY GLY GLY SER GLN ILE VAL SEQRES 12 A 257 LEU THR GLN SER PRO ALA ILE MET SER ALA SER PRO GLY SEQRES 13 A 257 GLU LYS VAL THR LEU THR CYS SER ALA SER SER SER VAL SEQRES 14 A 257 SER SER SER HIS LEU TYR TRP TYR GLN GLN LYS PRO GLY SEQRES 15 A 257 SER SER PRO LYS LEU TRP ILE TYR SER THR SER ASN LEU SEQRES 16 A 257 ALA SER GLY VAL PRO ALA ARG PHE SER GLY SER GLY SER SEQRES 17 A 257 GLY THR SER TYR SER LEU THR ILE SER SER MET GLU ALA SEQRES 18 A 257 GLU ASP ALA ALA SER TYR PHE CYS HIS GLN TRP SER SER SEQRES 19 A 257 PHE PRO PHE THR PHE GLY SER GLY THR LYS LEU GLU ILE SEQRES 20 A 257 LYS ARG ALA PRO HIS HIS HIS HIS HIS HIS HET B41 A 600 14 HETNAM B41 (2S)-1-(1,3-BENZODIOXOL-5-YL)-N-METHYLPROPAN-2-AMINE HETSYN B41 3,4 METHYLENEDIOXY-N-METHYLAMPHETAMINE; MDMA; ECSTASY FORMUL 2 B41 C11 H15 N O2 FORMUL 3 HOH *77(H2 O) HELIX 1 1 THR A 81 LYS A 83 5 3 HELIX 2 2 SER A 94 THR A 98 5 5 HELIX 3 3 SER A 170 SER A 172 5 3 HELIX 4 4 GLU A 220 ALA A 224 5 5 SHEET 1 A 4 VAL A 10 SER A 15 0 SHEET 2 A 4 LEU A 26 GLY A 34 -1 O THR A 33 N GLN A 11 SHEET 3 A 4 GLN A 85 LEU A 90 -1 O LEU A 90 N LEU A 26 SHEET 4 A 4 ILE A 75 ASP A 80 -1 N THR A 78 O TYR A 87 SHEET 1 B 6 LEU A 19 VAL A 20 0 SHEET 2 B 6 THR A 120 VAL A 124 1 O THR A 123 N VAL A 20 SHEET 3 B 6 ALA A 99 PHE A 106 -1 N TYR A 101 O THR A 120 SHEET 4 B 6 TYR A 41 GLN A 47 -1 N ILE A 45 O TYR A 102 SHEET 5 B 6 LEU A 53 SER A 60 -1 O ASP A 54 N ARG A 46 SHEET 6 B 6 THR A 65 TYR A 67 -1 O TYR A 66 N TYR A 58 SHEET 1 C 4 LEU A 19 VAL A 20 0 SHEET 2 C 4 THR A 120 VAL A 124 1 O THR A 123 N VAL A 20 SHEET 3 C 4 ALA A 99 PHE A 106 -1 N TYR A 101 O THR A 120 SHEET 4 C 4 TYR A 115 TRP A 116 -1 O TYR A 115 N TYR A 105 SHEET 1 D 4 LEU A 144 THR A 145 0 SHEET 2 D 4 VAL A 159 ALA A 165 -1 O SER A 164 N THR A 145 SHEET 3 D 4 SER A 211 ILE A 216 -1 O LEU A 214 N LEU A 161 SHEET 4 D 4 PHE A 203 SER A 208 -1 N SER A 204 O THR A 215 SHEET 1 E 6 ILE A 150 ALA A 153 0 SHEET 2 E 6 THR A 243 ILE A 247 1 O GLU A 246 N MET A 151 SHEET 3 E 6 ALA A 225 GLN A 231 -1 N ALA A 225 O LEU A 245 SHEET 4 E 6 LEU A 174 GLN A 179 -1 N TYR A 175 O HIS A 230 SHEET 5 E 6 LYS A 186 TYR A 190 -1 O TRP A 188 N TRP A 176 SHEET 6 E 6 ASN A 194 LEU A 195 -1 O ASN A 194 N TYR A 190 SHEET 1 F 4 ILE A 150 ALA A 153 0 SHEET 2 F 4 THR A 243 ILE A 247 1 O GLU A 246 N MET A 151 SHEET 3 F 4 ALA A 225 GLN A 231 -1 N ALA A 225 O LEU A 245 SHEET 4 F 4 THR A 238 PHE A 239 -1 O THR A 238 N GLN A 231 SSBOND 1 CYS A 30 CYS A 103 1555 1555 2.04 SSBOND 2 CYS A 163 CYS A 229 1555 1555 2.04 CISPEP 1 SER A 147 PRO A 148 0 0.40 CISPEP 2 PHE A 235 PRO A 236 0 0.07 SITE 1 AC1 10 TYR A 41 SER A 43 TYR A 55 TYR A 58 SITE 2 AC1 10 PHE A 106 GLU A 114 TYR A 177 HIS A 230 SITE 3 AC1 10 TRP A 232 PHE A 237 CRYST1 34.720 64.806 48.322 90.00 98.97 90.00 P 1 21 1 2 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.028802 0.000000 0.004546 0.00000 SCALE2 0.000000 0.015431 0.000000 0.00000 SCALE3 0.000000 0.000000 0.020951 0.00000